Advertisement

PharmacoEconomics Spanish Research Articles

, Volume 8, Issue 4, pp 117–126 | Cite as

Impacto presupuestario del uso de furoato de fluticasona para el manejo de la rinitis alérgica en atención primaria en España

  • Joaquim Mullol i Miret
  • Alicia Huerta Hernández
  • Isabel Pérez Escolano
Artículo de Investigación Original
  • 15 Downloads

Resumen

Objetivo: Evaluar los costes farmacológicos asociados al tratamiento de la rinitis alérgica (RA) con el corticoide intranasal furoato de fluticasona (FF) frente al tratamiento estándar, antihistamínicos orales (A-H1), en el ámbito de la atención primaria (AP) en España.

Métodos: Se desarrolló un árbol de decisión para estimar los costes farmacológicos asociados al tratamiento de un episodio de RA en AP con A-H1 o con FF desde la perspectiva del Sistema Nacional de Salud (SNS). El modelo se desarrolló en base a una revisión de la literatura, ensayos clínicos, guías de práctica clínica y bases de datos de análisis de mercado. Todos los supuestos fueron validados por un panel de médicos de AP expertos en el tratamiento de la RA.

Resultados: Un 55% de los pacientes en tratamiento con A-H1 requirió medicación concomitante, en comparación con el 37% de los pacientes en tratamiento con FF. El coste farmacológico medio de tratar un episodio de RA con A-H1 fue de 21,81 €/episodio mientras que el coste medio farmacológico con FF fue de 20,53 €/episodio, lo que resulta en una reducción de 1,28 €/episodio. Considerando que cada paciente con RA sufriese un episodio al año, el coste/año con A-H1 sería de 60,7 millones de € y el coste/año con FF de 57,1 millones de €, lo que equivaldría a una reducción de un 6% de los costes farmacológicos.

Conclusiones: El uso de FF como tratamiento de inicio en lugar del tratamiento estándar (A-H1) en AP puede representar una reducción significativa en la factura farmacéutica para el SNS, debido a una disminución en el uso de medicación concomitante.

Palabras clave

rinitis alérgica corticoide intranasal furoato de fluticasona costes 

Abstract

Objective: To estimate the impact of the intranasal steroid fluticasone furoate (FF) on the use of reimbursed medication versus standard treatment (oral antihistamines — A-H1) for the treatment of allergic rhinitis (AR) in Primary Care (PC) settings in Spain.

Methods: A decision tree model was developed to estimate the drug costs associated to the treatment of an RA episode with FF or A-H1 from the National Health Service (NHS) perspective. The model was built on epidemiology, clinical trials, treatment guidelines, and market research. Model assumptions were validated by an expert panel of PC physicians.

Results: 55% of patients with standard treatment needed concomitant medication versus 37% with FF during an episode of AR. Average A-H1 treatment costs per episode were €21.81, accounting for €60.7 million when patient population is treated in PC. The use of FF as a first line therapy could reduce treatment cost up to 6% due to a lower cost of €20.53 per episode.

Conclusions: The use of FF as a first line therapy for AR could represent a significant reduction in drug costs to the NHS due to the reduction in the use of concomitant medication.

Key words

allergic rhinitis intranasal corticosteroid fluticasone furoate costs 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliografía

  1. 1.
    Bousquet J, van Cauwenberge P, Khaltaev N, in collaboration with the WHO. Allergic rhinitis and its impact on asthma. J All Clin Immunol 2001;108:147–336.CrossRefGoogle Scholar
  2. 2.
    Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004;24:758–764.PubMedCrossRefGoogle Scholar
  3. 3.
    Bousquet J, Neukirch F, Bousquet PJ et al. Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol 2006; 117:158–162.PubMedCrossRefGoogle Scholar
  4. 4.
    Sibbald B, Rink E. Epidemiology of seasonal and perennial rhinitis: clinical presentation and medical history. Thorax 1991;46:895–901.PubMedCrossRefGoogle Scholar
  5. 5.
    Bousquet J, Khaltaev N, Cruz A et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008. Allergy 2008; 63: 8–160.PubMedCrossRefGoogle Scholar
  6. 6.
    Canonica GW, Mullol J, Pradolier A et al. Patient perception of allergic rinitis and quality of life. WAO Journal 2008; 138–144.Google Scholar
  7. 7.
    Szeinbach SL, Seoane-Vazquez EC, Beyer A, Williams PB. The impact of allergic rhinitis on work productivity. Prim Care Respir J 2007;16:98–105.PubMedCrossRefGoogle Scholar
  8. 8.
    Thompson AK, Juniper E, Meltzer EO. Quality of life in patients with allergic rhibitis. Ann Allergy Asthma immunol 2000; 85:338–348.PubMedCrossRefGoogle Scholar
  9. 9.
    Baiardini I, Braido F, Cauglia S et al. Sleep disturbances in allergic rhinitis, Allergy 2006; 61:1259–1267.PubMedCrossRefGoogle Scholar
  10. 10.
    Fineman SM. The burden of allergic rhinitis: beyond dollars and cents. Ann Allergy Asthma Immunol 2002; 88:2–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Soni A. Allergic rhinitis: trends in use and expenditures, 2000 and 2005. MEPS Statistical Brief 204 US Agency for Healthcare Research and Quality, 2008.Google Scholar
  12. 12.
    Stempel DA, Thomas M. Treatment of allergic rinitis: an evidence-based evaluation of nasal corticosteroids versus non-sedating antihistamines. Am J Manag Care 1998; 4:89–96.PubMedGoogle Scholar
  13. 13.
    Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rinitis: systematic review of randomized controlled trials. BMJ 1998; 317:1624–1629.PubMedCrossRefGoogle Scholar
  14. 14.
    Nielsen LD, Dahl R. Comparison of intranasal corticosteroids and antihistamines in allergic rhinitis: a review of randomized controlled trials. Am J Resp Med 2003; 2:55–65.Google Scholar
  15. 15.
    Wilson AM, O’Byrne PM, Parameswaran K. Leukotriene receptor antagonists for AR: a systematic review and metaanalysis. Am J Med 2004; 116:338–344.PubMedCrossRefGoogle Scholar
  16. 16.
    Yañez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol 2002; 89:479–484.PubMedCrossRefGoogle Scholar
  17. 17.
    Fokkens WJ, Jogi R, Reinartz S et al. Once daily fluticasone furoate nasal spray is effective in seasonal allergic rhinitis caused by pollen. Allergy 2007; 62:1078–1084.PubMedCrossRefGoogle Scholar
  18. 18.
    Kaiser HB, Naclerio RM, Given J et al. Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 2007; 119:1430–1437.PubMedCrossRefGoogle Scholar
  19. 19.
    Keith PK, Scadding GK. Are intranasal corticosteroids all equally consistent in managing ocular symptoms of seasonal allergic rhinitis?. Curr Med Res Opinion 2009; 25:2021–2041.CrossRefGoogle Scholar
  20. 20.
    Garris C, Shah M, D’Souza A et al. Comparison of corticosteroids nasal sprays in relation to concomitant use and cost of other prescription medications to treat allergic rhinitis symptoms. Clin Drug Invest 2009; 29:515–526.CrossRefGoogle Scholar
  21. 21.
    Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices — budget impact analysis. Value in Health 2007; 10:336–347.PubMedCrossRefGoogle Scholar
  22. 22.
    Pinto JL, Sánchez F. Métodos para la evaluación económica de nuevas prestaciones. Editado por Centre de Recerca en Economia i Salut — CRES y Ministerio de Sanidad y Consumo, España. Disponible en: http://www.msc.es/estadEstudios/estadisticas/docs/metodos_evaluacion.pdf.
  23. 23.
    Mullol J. A survey of the burden of allergic rhinitis in Spain. J Invest Allergol Clin Immnunol 2009; 19:27–34.Google Scholar
  24. 24.
    Bousquet J, Annesi-Maesano I, Carat F et al. Characteristics of intermittent and persistent allergic rhinitis: DREAMS study group. Clin Exp Allergy 2005; 35:728–732.PubMedCrossRefGoogle Scholar
  25. 25.
    Instituto Nacional de Estadística. Cifras de población y censos demográficos. Disponible en: http://www.ine.es (fecha consulta: 01 Julio 2009).
  26. 26.
    Canonica GW, Bousquet J, Mullol J. A survey of the burden of allergic rhinitis in Europe. Allergy 2007; 62:17–25.PubMedCrossRefGoogle Scholar
  27. 27.
    Schatz M, Meltzer EO, Nathan R et al. Psychometric validation of the rhinitis control assessment test: a brief-completed instrument for evaluating rhinitis symptom control. Ann Allergy Asthma Immunol 2010; 104:118–124.PubMedCrossRefGoogle Scholar
  28. 28.
    Negro Alvarez JM. Estudio RINOASMAIR. Disponible en: http://alergomurcia.com/pdf/CURSO_PRIMARIA_2007_26.pdf
  29. 29.
    Castillo JA, Molina J, Mullol J. Prevalence and characteristics of rhinitis in asthmatic patients attending primary care in Spain (the RINOASMAIR study), Rhinology 2010 48: 35–40.PubMedGoogle Scholar
  30. 30.
    IMS Health Dataview. Datos de ventas y prescripción en España Septiembre 2008 a Mayo 2009.Google Scholar
  31. 31.
    Base de Datos del Medicamento del Consejo General de Colegios Oficiales de Farmacéuticos — Catálogo de Especialidades Farmacéuticas. Disponible en: https://botplusweb.portalfarma.com
  32. 32.
    Simoens S, Laekeman G. Pharmacotherapy of allergic rhinitis: a pharmaco-economic approach. Allergy 2009; 64:85–95.PubMedCrossRefGoogle Scholar
  33. 33.
    Schoenwetter WF, Dupclay L, Appajosyula S et al. Economic impact and quality-of-life burden of allergic rhinitis. Curr Med Res Opinion 2004; 20:305–316.CrossRefGoogle Scholar
  34. 34.
    Schramm B, Ehlken B, Smala A et al. Cost of illness of atopic asthma and seasonal allergic rhinitis in Germany: 1-yr restrospective study. Eur resp J 2003; 21:116–122.CrossRefGoogle Scholar
  35. 35.
    Bousquet J, Demarteu N, Mullol J et al. Costs associated with persistent allergic rhinitis are reduced with levocetirizine. Allergy 2005; 60:788–974.PubMedCrossRefGoogle Scholar
  36. 36.
    Lange B, Lukat KF, Retting K et al. Efficacy, cost-effectiveness and tolerability of mometasone furoate, levocabastine and disodium cromoglycate nasal sprays in the treatment of seasona allergic rhinitis. Ann Allergy Asthma Immunol 2005; 95:272–282.PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  • Joaquim Mullol i Miret
    • 1
  • Alicia Huerta Hernández
    • 2
  • Isabel Pérez Escolano
    • 2
  1. 1.Servicio de Otorrinolaringología - Hospital Clinic i Provincial, IDIBAPS, CIBERESUnidad de Rinología y Clínica del OlfatoBarcelonaEspaña
  2. 2.Departamento de Evaluación de Medicamentos - GlaxoSmithKlineTres Cantos (Madrid)España

Personalised recommendations